This study is about testing a new medication called rocatinlimab for people with bad asthma, a condition that makes it hard to breathe. The goal is to see if this medicine helps reduce asthma attacks. Participants need to be aged between 18 to 75 years and have been diagnosed with asthma for at least a year. They should already be on asthma treatments like inhaled corticosteroids (a type of medicine that helps reduce inflammation in the lungs) and have had at least one asthma attack in the past year. However, people who have been recently hospitalized for asthma, are current smokers, or have other lung diseases cannot join. The study involves taking rocatinlimab and attending several visits to track progress. It's important to consider the time commitment and any potential risks before joining.

• The study lasts several months with multiple visits.
• Participants must already be on certain asthma medications.
• There are specific health conditions that disqualify participation.